1. Using MHC Molecules to Define a Chlamydia T Cell Vaccine.
- Author
-
Karunakaran KP, Yu H, Foster LJ, and Brunham RC
- Subjects
- Animals, Bone Marrow Cells cytology, Cloning, Molecular, Computational Biology, Dendritic Cells cytology, Female, Histocompatibility Antigens genetics, Histocompatibility Antigens isolation & purification, Immunization, Mice, Mice, Inbred C57BL, Mycobacterium tuberculosis cytology, Mycobacterium tuberculosis metabolism, Proteomics, Recombinant Proteins genetics, Recombinant Proteins immunology, Recombinant Proteins isolation & purification, Salmonella cytology, Salmonella metabolism, Bacterial Vaccines immunology, CD4-Positive T-Lymphocytes immunology, Chlamydia trachomatis immunology, Histocompatibility Antigens immunology
- Abstract
Vaccines based on humoral immunity alone are unlikely to protect against infections caused by intracellular pathogens and today's most pressing infectious diseases of public health importance are caused by intracellular infections that include tuberculosis, malaria, HIV/AIDS, and others such as Chlamydia trachomatis. For these infections, vaccines that induce cellular immune responses are essential. Major impediments in developing such vaccines include difficulty in identifying relevant T cell antigens and delivering them in ways that elicit protective cellular immunity. Genomics and proteomics now provide tools to allow unbiased empirical identification of candidate T cell antigens. This approach represents an advance on bioinformatic searches for candidate T cell antigens. This chapter discusses an immunoproteomic approach we have used to identify Chlamydia T cell antigens. We further discuss how these T cell antigens can be developed into a human vaccine.
- Published
- 2016
- Full Text
- View/download PDF